NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today the appointment of Joseph Akers as a new member of the Board of Directors. Mr. Akers will serve on the Audit Committee and Chair the Compensation Committee.
